Clinical trials demonstrate safety and efficacy of Ebola Zaire vaccines

Two vaccines against the Zaire strain of Ebola virus are immunogenic and safe in both adults and children, according to initial results from two phase II clinical trials published in the New England Journal of Medicine.

Ad26.ZEBOV (Ad26) followed by MVA-BN-Filo (MVA) 56 days later and rVSVΔG-ZEBOV-GP (rVSV) given with or without a booster dose 56 days later produced antibody responses as early as two weeks following administration of the first dose of vaccine which lasted for at least one year.

Both vaccine regimens were safe and well-tolerated.

These findings, revealed as part of the PREVAC study in West Africa, may help optimize vaccine strategies to fight Ebola virus disease (EVD), and minimize the high death rates associated with outbreaks of the Zaire strain.

PREVAC (Partnership for Research on Ebola Vaccinations) is a consortium of health authorities in four countries in West Africa — Guinea, Liberia, Sierra Leone and Mali — working alongside international partner organizations including the London School of Hygiene & Tropical Medicine (LSHTM), the U.S. National Institutes of Health and the French National Institute of Health and Medical Research.

Launched in 2017, the PREVAC study aims to compare the safety and efficacy of three different experimental regimens of Ebola Zaire vaccine versus placebo.

Overall, 2801 volunteers at six sites in Guinea, Liberia, Sierra Leone and Mali, were recruited into two, randomized phase II clinical trials: one involving 1400 adults (median age of 27 years, 45% women) and the other involving 1401 children aged one year or older (median age of 8 years, 46% female).

Participants received either Ad26 (supplied by Janssen) followed by MVA (supplied by Bavarian Nordic) eight weeks later, one dose of rVSV (supplied by Merck Sharp & Dohme) followed by placebo eight weeks later, or two doses of rVSV separated by eight weeks.

Drug Discovery eBook

Compilation of the top interviews, articles, and news in the last year.

Download a free copy

Regimens of Ad26 plus MVA and rVSV produced antibody responses in participants from week two following first injection. Peak response rates occurred at around month three for Ad26 plus MVA in adults and children, at day 28 for rVSV in adults and children in the single dose group and at day 63 in adults and children in the rVSV booster group. By 12 months, antibody responses were still well maintained in all groups.

Reported side effects, such as fever and headaches, were mild, temporary and similar to previous vaccine studies.

Although the findings are promising, the authors emphasize that they were unable to assess how these vaccines might protect against EVD directly as no cases of the disease were recorded in the trial and the exact level of antibody response needed to induce protective immunity is still unknown.

Long-term follow up of the participants in this trial is taking place to determine if and when booster doses might be needed. The availability of safe and effective Ebola vaccines for both children and adults is an important step forward in being able to prevent and/or contain future outbreaks of Ebola infection."

Professor Brian Greenwood, Co-Author and Professor of Clinical Tropical Medicine, LSHTM

Please note that the vaccines investigated in PREVAC are against the Zaire strain of Ebola virus and not the Sudan strain implicated in the current outbreak in Uganda.

Further information on the PREVAC Consortium can be found here. A follow-up study, PREVAC-UP, will continue to monitor participants over a five-year period to assess whether these initial safety and efficacy results can be maintained in the long-term.